PRKAR1A and ovarian carcinoma: In summary, this work demonstrated that TSE1 had more potent inhibitory effects on the platinum-resistant ovarian cancer OVCAR-3 and A2780/CP70 cells than cisplatin, and was less cytotoxic to normal ovarian IOSE-364 cells.